Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Repevax + Revaxis
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Repevax and Revaxis are booster vaccines developed by Sanofi Pasteur, designed to maintain protective immunity against several life-threatening bacterial and viral infections. Repevax is a quadrivalent vaccine (dTaP-IPV) containing reduced doses of diphtheria and tetanus toxoids, acellular pertussis antigens, and inactivated poliovirus; it is typically administered as a booster to children and adolescents. Revaxis is a trivalent vaccine (Td-IPV) containing reduced doses of diphtheria and tetanus toxoids along with inactivated poliovirus, but notably lacks the pertussis component; it is used for booster immunization in older children, adolescents, and adults. Both vaccines utilize reduced antigen content compared to primary series vaccines, making them suitable for booster doses to maintain long-term immunity. They contain toxoids and inactivated viruses adsorbed onto aluminum salts to enhance the immune response.
- Brand names
- Adacel-Polio
- Other names
- dTaP-IPVTd-IPV
02
Targets
PRN (Pertactin)FIM2/FIM3 (Fimbriae types 2 and 3)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Repevax + Revaxis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Repevax + Revaxis.